MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection ...
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx ...
On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnostics, Inc. from Bio-Techne, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related ...
MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of ...
A recent BBC investigation questioned the accuracy of prostate-specific antigen (PSA) self-tests – rapid at-home tests for men worried about prostate cancer. The BBC analysed five of these tests using ...
Fear of recurrence among uninsured and underrepresented prostate cancer survivors of the Men's Health Study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results